Schering-Plough of the USA has dedicated a new $200 million bulkpharmaceutical manufacturing facility in Tuas, Singapore. The plant will produce a wide range of bulk pharmaceutical products, and strengthens the company's ability to compete in international markets, especially in Asia and the Pacific Basin. Three products that will be manufactured there are the non-sedating antihistamine Claritin (loratadine), the prostate cancer treatment Eulexin (flutamide), and the antiasthma agent Proventil (albuterol sulfate), and a number of dermatological products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze